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Abstract
Inducible cAMP early repressor (ICER) is an endogenous repressor of cAMP- 
responsive element (CRE) with antiproliferative properties that acts as a potential 
suppresser for tumors especially melanoma. ICER activity and cellular localization are 
orchestrated by the performance of the post-translational modifications (PTMs). 
Ubiquitination and sumoylation are two of the most important types of PTMs that control 
diverse groups of biological processes for ICER protein. The goal of this project is to study 
how post-translational modifications alter the function of the transcriptional repressor 
Inducible cAMP Early Repressor (ICER) in melanoma cells. Since ICER ubiquitination 
and sumoylation processes take place on the interaction between the ubiquitin and the 
lysine residues of ICER amino acid sequence, my interest was focused on the downstream 
targets of each ICER mutants. Through the application of site-directed mutation to the 
multiple ubiquitination positions of the amino acid Lysine (K) and replacing them by 
Arginine (R). Then, ICER’s wild type and mutant DNA were transfected into human 
mammalian model melanoma cells; SK-MEL-24 and subjected to immunocytochemistry, 
Western Blot and half-life analyses to further understand the modification and regulatory 
nature of ubiquitination and sumoylation pathways. The results presented an insight on the 
cellular distribution of ICER mutants’ expression as well as hinted at the importance of 
ubiquitination and sumoylation in terms of ICER stability.
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Introduction
Although many people might think that all important human body’s organs are 
embedded internally, our skin; on the other hand, is the external coat that surrounds our 
flesh and shapes our familiar human body appearance. Because human skin is considered 
the largest and the heaviest of all other organs, its significance goes beyond its role in 
making us look presentable in an intact human figure (1). Our skin not only maintains the 
normal body moisture, it also insulates and guards it against the harsh environment 
conditions such as temperature, sunlight damage and chemicals. In addition, our skin 
secrets different types of substances that protects it against various numbers of infections 
caused by bacteria or other invading microorganisms (2). Furthermore, the skin is our main 
source of vitamin D production, the key sensory center in our bodies and an essential tool 
for free body movements. Hence, our skin provides crucial and versatile functions allowing 
us to survive and live a healthy life (2).
However, skin -like any other organ- is highly susceptible to several diseases and 
abnormalities that require fast therapeutic care to prevent serious consequences which 
might lead to sudden death (3). One of the most common skin diseases is melanoma or skin 
cancer (4). It results from an uncontrolled differentiation of melanocyte cells with 
unlimited ability to invade the nearby healthy tissues and form cancerous lesions (4). 
Melanocytes are specialized cells found in the epidermal layer of the skin that is 
responsible for the production of the brown pigmentation of our skin known as melanin. 
They are also responsible for generating different skin colors with remarkable variations 
as well as the production of moles (5). Melanoma has two stages of development; the first 
stage is called benign and can be treated and controlled, the second stage called malignant
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and results when the patient at the benign stage is left untreated (6). Melanoma occurs due 
to abnormal genetic mutations in the melanocytes (7). The process begins in the skin where 
a mole containing melanocyte cells is activated by UV radiation (7). When the tumor 
becomes invasive, it grows and penetrates vertically affecting other vital organs through a 
process called metastasis (8). The main cause of mutation is still not very clear, but recent 
research studies have confirmed that it could be due to the direct exposure to the sunlight, 
which contains an ultraviolet (UV) radiation that destroys or alters the melanocytes in such 
a way that lead to an over-expression and consequently unlimited cellular divisions (9). 
Some research studies have also suggested that melanoma may develop from the fact that 
this disease can be genetically inherited from one or two parents who happened to have 
melanoma or other types of cancer (10). Melanoma can differ by gender in terms of 
location; in men, it might be found in the trunk area of the body and in women it can most 
likely be found on the back and leg areas (11). Melanoma can also differ by percentage 
between men and women and it has been estimated that men are more likely to develop 
melanoma than women by a factor of 55%. Epidemiologists have also confirmed that 
melanoma is ranked as the sixth and seventh leading cause of mortality in men and women, 
respectively (11). Moreover, in a new statistical study conducted in the United States in 
2016 the total number of new melanoma cases was estimated to reach 76,380 with 
California (8,560) and Florida (6,200) scoring the highest numbers followed by New York 
(4,250) and Pennsylvania (3,750) (12). In addition to gender, race and age play critical 
roles in melanoma susceptibility. For instance, Caucasian individuals are more prone to 
have melanoma due to the fair skin that produces lower amounts of melanin pigmentation 
that is essential to protect against UV exposure (5). Furthermore, an individual’s age can
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also indicate the predisposition to melanoma whereas it has been estimated that adults 
between 55 to 74 years-old are the most affected group (5).
In recent years, the incidence of melanoma has continued to increase rapidly. 
Scientists have been searching for new methods to eradicate this disease. Many on-going 
research studies and clinical trials have been used and practiced in the treatment of 
melanoma resulting in slightly reduced patient susceptibility but not curing the patients (4). 
Different approaches can be applied in the hopes to specifically target cancerous cells and 
effectively kill them can be divided into two groups; the first involves the use of the 
traditional approaches which includes: chemotherapy, radiation, and surgery (13). While 
the second involves the application of modem molecular approach that utilizes stem cells, 
bone marrow transplanting, immunotherapy and gene therapies that are clinically designed 
to target specific genes and proteins, in cancer cells, that directly participate in cellular 
mechanisms such as uncontrolled cell proliferation, declined apoptotic levels and unlimited 
tumor growth (13,14). The focus of this project is on the gene therapy approach to study 
and investigate melanoma cells in vitro using human model cancer cells.
Previous studies have suggested that the development of melanoma and other 
cancer types relate directly to one of the most critical cellular processes called 
posttranslational modification (PTM) (15). Those processes, along with protein 
degradation, allow rapid regulation of different physiological processes in a way that 
maintains body homeostasis by means of adaptation to the surrounding environments. 
Therefore, PTMs provide specific and effective biological responses to either external or 
internal stimuli which make them responsible for altering protein function, activity, 
stability and their subcellular localization (16). PMTs modify proteins by attaching or
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tagging a variety of functional groups to their targeted amino acid sequences in order to 
interfere with their function or structure and consequently regulate them to serve cellular 
demands (16). Moreover, PTMs are divided into two types; reversible and irreversible. 
Among all identified reversible PTMs in mammals, ubiquitination and sumoylation are two 
of the most frequent modifications that regulate the activity of proteins (16). The function 
of ubiquitination is to recognize and covalently attach to lysine (K) residues of a protein 
with ubiquitin, a small protein of 76 amino acids with a molecular weight of 8.5 KDa that 
is expressed widely in all mammalian tissues. The C-terminus of the ubiquitin contains 
glycine that is critical for its attachment to a substrate as well as to another ubiquitin 
molecule (17). The attachment employs a set of three enzymes; ubiquitin activating enzyme 
(El), ubiquitin conjugating enzyme (E2), and ubiquitin ligase (E3). The process begins 
when El forms a thio-ester bond with the ubiquitin and leads to the binding of ubiquitin to 
E2, which in turn, allows the formation of an isopeptide bond between the lysine residue, 
which is required for further formation of the polyubiquitin, and the c-terminus of the 
ubiquitin and requires E3 (18).These ubiqitinated proteins are either polyubiquitinated 
forming a chain and allowing the cell to signal for protein unfolding and degradation 
through proteasome multi-subunit or monoubiquitinated to a smaller fragment that 
undergoes endocytosis, involved in DNA damage or even altering the subcellular 
localization (19). After the protein is degraded, the ubiquitin dissociates through 
deubiquitinating process and cycles back to be used again by the cell whenever is needed 
(16).
On the other hand, sumoylation also labels the protein with a small ubiquitin-like 
motif with a molecular weight of 10 KDa, hence the name, however, it does not degrade
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the protein, rather, it regulates the functional properties of proteins which involve 
subcellular targeting and protein-protein interactions (20, 21).
Furthermore, research studies suggested that ubiquitination and sumoylation are 
dysregulated leading to tumor growth and tumorigenesis, which includes an abnormal 
progression of cell cycle, programmed cell death, and blocking different types of crucial 
receptors (21). Therefore, researchers and scientists spent great effort to understand and 
investigate the molecular and biological basis of these two processes in the field of cancer 
and especially in melanoma raising the potential that these pathways can be employed for 
the therapeutic practices in order to eradicate cancer (21).
The goal of this project is to study and investigate how the two post-translational 
modifications; ubiquitination and sumoylation can alter the function and cellular 
localization of the transcriptional repressor Inducible cAMP Early Repressor (ICER) in 
human melanoma cells. ICER is a part of the transcription factor of the cyclic AMP 
response element (CRE) binding protein (CREB) and CRE modulator (CREM) (22). 
CREB and CREM are phosphorylated by protein kinase A (PKA), which in turn, indirectly 
activates the transcription of ICER and other CRE-involving proteins (23). ICER acts as a 
transcript and auto-regulates CREM and has been found in four discrete isoforms, 
including; ICER-I, ICER-II, ICER-Iy and ICER-IIy (23, 24). ICER has a protein structure 
consisting of leucine zipper with a molecular weight o f-18.5 KDa (25). ICER only contains 
a homodimer of DNA binding domain (DBD) allowing it to function as a strong dominant 
negative transcriptional repressor for cAMP (26). Since ICER has neither activation 
domain nor the phosphorylation (P)-box site, its protein activity can be detected through 
its intracellular concentration which in turn relies on ICER degradation levels (25).
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Previous studies have shown that ubiquitination and sumoylation are the two main 
pathways for ICER degradation (25). Furthermore, previous evidence showed that ICER 
abnormal protein expression is involved in tumorigenesis because its levels drop in human 
cancer cells due to phosphorylation by either mitogen-activated protein (MAP) kinase 
which leads to ubiquitin-mediated proteasomal degradation of ICER or by mitotic kinase 
cdkl which results in monoubiquitination of ICER causing it to mis-locate in the cytoplasm 
(27). In addition, altering the enzymatic system of sumoylation pathway upon intracellular 
or extracellular stimuli or cellular transduction with other post-translational modification 
mechanisms like ubiquitination leads to imbalanced transcriptional activities which in turn 
results in melanoma progression (28). Even though the isoform ICER-IIy has the functional 
characteristics of a tumor suppressor, there is no genetic evidence to demonstrate that ICER 
is a tangible tumor suppressor gene product (29). Moreover, studies have indicated that the 
proliferative characteristics of the melanocyte cells are mainly regulated by the cAMP 
pathway where ICER is directly involved in the activation of cell cycle (30).
Our interest was focused on the downstream targets of each ICER mutant. This was 
accomplished by applying site-directed mutation where eleven ubiquitination positions, 
including K0-(52, 59, 70, 71, 72, 76, 87, 90, 97, 100 and 106) of the amino acid Lysine (K) 
were replaced by Arginine (R) in ICER protein. ICER’s wild type and mutant DNA were 
transfected into the mammalian model melanoma cells SK-MEL-24. Then, a series of in 
vitro analyses with both wild type and mutated ICER were conducted using Western blot, 
and half-life techniques in order to investigate whether these mutations are affected by 
ubiquitination and sumoylation.
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Materials and Methods
Cell line and culture
The cells were purchased from the American Type Culture Center company. The 
SK-MEL-24 cells were harvested from the skin tissue of a 76-old Caucasian male’s lymph 
node who developed malignant melanoma. The media was nourished with Earle's BSS with 
nonessential amino acids and sodium pyruvate, 85%; fetal bovine serum, 15% and 
preserved in 5% DMSO (34).
Site-directed Mutagenesis and DNA vector of ICER-Iy mutants
ICER mutants were prepared by Fanaye Woldeamanuel (36) who previously 
worked on the research where the ubiquitination sites of ICER were first located and 
represented by the amino acid lysine (K) at 11 positions as follows (Picture 1):
M A VT GDET A A 10 TGDMPTYQIR20 APTTALPQGV30 VMAASPGSLH40
SPQQLAEEAT50 RKRELRLMKN60 REAARECRRK70 KKEYVKCLEN80
RVAVLEKQNK90 TLIEELKALK100 DLYCHKAE110
Picture 1: Amino acid sequence of ICER. The ubiquitination sites of ICER represented by the Lysine residue (K) and 
were highlighted in red.
Then a site-directed mutagenesis procedure was carried out and each lysine (K) 
residue was replaced by arginine (R) residue and the knockout mutant was denoted as KO 
followed by the position of the mutation as follows: KO-52, KO-59, K0-70, KO-71, KO-72, 
KO-76, KO-87, K0-90, KO-97, K0-100 and K0-106, in addition to a mutant that had 
mutation at all lysine (K) sites which was denoted as KO.
The vectors of ICER mutants were also designed and prepared by previous research 
students where a cytomegalovirus (CMV) promoter was fused to a reporter with a group of 
DNA fragment each containing an ICER mutant. The DNA vectors were designed and
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attached to the human influenza hemagglutinin (HA) epitope tag to further facilitate the 
detection and identification of ICER mutants from other non-specific proteins after the 
incubation with the anti-HA antibodies. To accomplish that, two groups were generated 
where the HA-tag was placed on the N-terminus of the DNA fragment including the 
wildtype denoted as NWT, lysine knockout at all ubiquitination positions denoted as NKO 
and lysine knockout at the following ICER ubiquitination positions denoted as: NKO-52, 
NKO-59, NK0-70, NKO-71, NKO-72, NKO-76, NKO-87, NK0-90, NKO-97, NKO-100 and 
NKO-106 and on the C-terminus of the DNA fragment including the wildtype denoted as 
CWT and lysine knockout at all positions denoted as CKO. The stock solution of the 15 
ICER constructs was then obtained from Invitrogen ™ Life Technologies company (35).
Non-Liposomal Transfection (Cationic liposome)
The SK-MEL-24 cell cultures were grown one day before so that the cells could be 
confluent by the time the transfection was started. The DNA of each ICER mutant was 
diluted to 2pg per 100 pL of serum free media which contained phenyl red. Later the serum 
free media was changed and 90pL of serum was used instead. Then 8pL of fugene® HD 
Transfection Reagent from Promoga company was added to each well and incubated for 
20 minutes. There was a waiting period of 48 hours before measuring the results. The total 
volume of the DNA, serum and fugene® HD Transfection Reagent was calculated to be 
lOOpL.
Indirect Avidin-Biotin Complex (ABC) Immunocytochemistry
As mentioned earlier, the cells were grown in culture plates and transfected. After 
transfection, the medium was removed and the cells were washed 2 times with Phosphate- 
buffered saline (PBS) at room temperature. Then the cells were fixed by adding 4% (v/v)
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formaldehyde in PBS using the same volume as the culture medium and incubated for 20 
minutes. The fixative was removed and washed 3 times with PBS. Sodium Azide was used 
in PBS to store the cells. The antigen retrieval buffer was reheated and 1 mL was added to 
each cell culture. This mixture was heated at 95 °C for 10 minutes. The buffer was then 
removed and cells were again washed 3 times with PBS. The cells were later incubated in 
0.1% Triton X-100 in PBS for 15 minutes at room temperature. After the incubation, the 
cells were rinsed 3 more times with PBS. Then the remaining PBS was removed and protein 
block was applied to the cells. Then the cultures were incubated for 1 hour at room 
temperature. Later, polyclonal Rabbit anti-HA (primary antibody) obtained from the 
ab64261 - Rabbit Specific HRP/DAB (ABC) Detection IHC Kit was added and the cultures 
at room temperature for 2 hours. After the incubation, the cells were washed 4 times with 
2 mL PBS. Biotinylated Goat Anti-Polyvalent (secondary antibody) obtained from the 
ab64261 - Rabbit Specific HRP/DAB (ABC) Detection IHC Kit was applied to the cells 
and incubated for 10 minutes at room temperature and the cultures washed 4 times with 
PBS. Later Streptavidin Peroxidase solution was then obtained from the ab64261 - Rabbit 
Specific HRP/DAB (ABC) Detection IHC Kit, added to the cells and incubated for 10 
minutes at room temperature. The cells were once again washed with PBS 4 times. One 
drop of DAB Chromogen was added to 50 drops DAB substrate obtained from ab64261 - 
Rabbit Specific HRP/DAB (ABC) Detection IHC Kit and this mixture was added to the 
cells. The cells were incubated with the mixture for about 10 minutes and then rinsed 4 
times with PBS. Finally, a drop of mounting medium was added to the slide and observed 
under the microscope.
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NE-PER Nuclear and Cytoplasmic Extraction
The SK-MEL-24 cells were grown on a T25 flask and were transfected following 
the same procedure previously mentioned. Then the culture medium was removed and the 
cells were washed once with 2 mL PBS at room temperature. After that, 1 mL of trypsin- 
EDTA was added and the mix was incubated for 3 minutes at room temperature. Then, 2 
mL of complete cell culture media was added to the cultures and mixed by pipetting up 
and down gently. The mixture was transferred to a 15 mL tube and centrifuged at 500 x g 
for 2.5 minutes. After this, lmL of ice-cold PBS was added to the cells and transferred to 
a 1.5 mL Eppendorf tube and centrifuged at 500 xg for 2.5 minutes. As much supernatant 
as possible was pipetted out and discarded. Later, lOOpL of ice-cold CER I was added to 
the pellet and vortexed for 15 seconds to suspend the cell. The mixture was then incubated 
on ice for 10 minutes and 5.5 pL of ice-cold CER II was added to the mixture. The tube 
was again vortexed for 5 seconds and incubated for 1 minute. Then the mixture, vortexed 
again for 5 seconds and centrifuged for 5 minutes at maximum speed. The supernatant was 
collected immediately after centrifugation and stored in a clean pre-chilled tube. This was 
the cytoplasmic extract. The pellet was resuspended in 50 pL of ice-cold NER and vortexed 
for 15 seconds. The sample was put on ice and was vortexed every 10 minutes for 15 
seconds, for a total of 40 minutes. Later, it was centrifuged at maximum speed for 10 
minutes and the supernatant was collected and placed in a clean pre-chilled tube. This was 
the nuclear extract.
Near-Infrared Western Blot Analysis (NIWB)
Protein extractions were prepared from nucleus and the cytoplasm and were loaded 
into each well of the 4-20% polyacrylamide-SDS gel in addition to the ladder. The gel then
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was run following the manufacturer’s procedure (37). After that, the gel was transferred 
into the blotting membrane and was run following the manufacturer’s procedure. The 
membrane was then incubated with the primary Rabbit-anti HA antibody (lug/mL of LI- 
COR blocking buffer) that was previously prepared and obtained from Invitrogen ™ 
company for 4-6 hours while rock/shock on a shaker at room temperature. It was then 
incubated with previously prepared IRDye® 800CW Goat Anti-Rabbit IgG (H + L) 
secondary antibody obtained from the LI-COR company (1 pL in 10 mL of LI-COR 
blocking buffer). The membrane was then incubated for 30-45 minutes on the shaker at 
room temperature. Then, the membrane was dried out by placing it between two paper 
towel sheets and visualized under the infrared radiation using the device Odyssey® CLx 
scanner by detecting the fluorescent dye of the secondary antibody at its excitation 
wavelength of 676 nm. After that, immunoblotted pictures were generated using the 
software Odyssey® CLx imaging system that was provided with the device. The intensity 
of each band was obtained using the software Odyssey® CLx imaging system and was 
accomplished by highlighting the area with dark band using the rectangular option found 
in the software program. A table then formulated with the collected data using Microsoft 
Excel software.
Half-life cycloheximide (CHX) Chase Assay
The cell cultures for SK-MEL-24 cells were transfected as mentioned previously. 
Then the cells were treated with CHX (lOpg/mL) to inhibit the de novo protein synthesis. 
Next, the cells were harvested at the following time profile: 0, 1, 3 and 6 hours. After that, 
the harvested cells underwent Near- Infrared Western Blotting analysis (as mentioned 
earlier) to collect the data. The visualization of Western Blot membrane was accomplished
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using the near infra-red device Odyssey ® CLx scanner following the same steps 
mentioned in the previous experiments. The intensity o f each band was obtained by 
highlighting the area with dark band using the rectangular option found in the Odyssey® 
CLx imaging system and then formulated a table with the collected data using Microsoft 
Excel software.
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Results
Transfection of ICER plasmid mutants into SK-MEL-24 cells
Recent research experiments show that human melanoma cells harvested from 
various types of patients provide a versatile tool for studying morphology, gene expression, 
and cellular and physiological modifications (31). To insert ICER constructs and further 
investigate how they can be expressed, we performed an in vitro transfection of the SK- 
MEL-24 cells with ICER mutant. First, site-directed mutation was made for the 
ubiqitinated sites of ICER (KO-52, 59, 70, 71, 72, 76, 87, 90, 97, 100 and 106) as well as 
CWT, NWT, CKO and NK0. Next, the plasmids were ordered from the ThermoFisher 
Scientifics company and tagged with Green Fluorescent Protein (GFP) following a similar 
procedure as the HA-tag (See materials and methods). To test for the viability of the 
transfected SK-MEL-24 cells, we applied a chemical non-liposomal transfection technique 
using FuGENE®HD Transfection Reagent. Fluorescent imaging method was conducted 
using Phase Contrast microscopy to obtain spatial localization for ICER samples K0-(52, 
59, 70, 71, 72, 76, 87, 90, 97, 100 and 106), NWT, CWT, NK0 and CKO and the control 
sample which only contained SK-MEL-24 cell with GFP-tagged ICER and the total cell 
count for each ICER mutant was estimated (Table 1). The data showed that KO-72, KO-71 
and CWT had the highest number of transfected fluorescent cells calculated to be 332, 226 
and 266 respectively. The second group consisting of KO-59, K0-100 and K0-70 constructs 
had average numbers of transfected cells with values 145, 155 and 112 respectively. The 
remaining ICER mutants K0-(52, 76, 87, 90, 97 and 106), NK0, CKO and NWT had the 
lowest and insignificant numbers of transfected SK-MEL-24 cells (Table 1). These results
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suggested that these mammalian cells could have inserted ICER plasmid into their DNA 
with different affinities altered by the change in the amino acid at each ubiquitination site.
Furthermore, to determine how SK-MEL-24 cells were efficient in taking up theses 
ICER mutants, transfection efficiency (TE) was calculated. The values of TE were obtained 
by dividing the number of the fluorescent cells by the total cell count number obtained 
from Phase Contrast microscopy imaging (Table 1). The TE of KO-72, KO-71 and CWT 
samples were high and calculated to be 85%, 65% and 75% respectively indicating that the 
SK-MEL-24 cells were successfully transfected with ICER DNA. These results were 
followed by transfection efficiencies with average values of 40% for KO-59 and K0-100 
and 35% for K0-70. These results, in turn indicated that SK-MEL-24 cells have selectable 
characteristics for ICER induction proving that they can be employed as a model cell for 
studying melanoma.
Table 1: Transfection of ICER mutants into SK-MEL-24 cells.
Sample Cell Count Total # of Cells
% Transfection 
Efficiency
NKO 75 125 60%
CKO 13 125 10%
NWT 62 246 25%
CWT 266 355 75%
KO-52 84 167 50%
KO-59 145 363 40%
K0-70 112 321 35%
KO-71 226 347 65%
KO-72 332 390 85%
KO-76 52 264 20%
K0-8 7 96 275 35%
K0-90 92 366 25%
KO-97 56 223 25%
K0-100 155 387 40%
KO-106 14 142 10%
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Visual localization ofICER mutants in SK-MEL-24 cells
Previous studies suggested that ICER can be expressed in the nucleus of 
mammalian cells (32). To test this hypothesis, we sought to assess the subcultural 
localization ofICER mutants using Immunocytochemistry (ICC) technique. The SK-MEL- 
24 cells were first transfected with HA-tagged ICER mutants; CKO, NKO, NWT, CWT, 
K0-(52, 59, 70, 71,72, 76, 87, 90, 97, 100 and 106). Then, an ABC immunocytochemistry 
method was applied to the transfected cells. Each transfected cell was viewed under the 
light microscopy for visual analysis. The obtained immunostaining images showed 
different subcellular distributions and localizations of all ICER mutants under 200X 
magnification (Fig. 1). Then, the average number of cytosolic and nuclear localization for 
ICER mutants was collected and calculated from 5 different locations of each sample 
(Table 2). The data indicated that most SK-MEL-24 cells had nuclear localization for ICER 
mutants, including; CWT, KO-97, and kO-87, which showed elevated numbers of SK-MEL- 
24 cells that expressed ICER in the nucleus with values of 44, 40 and 35 respectively (Fig. 
2). These results indeed, agreed with the previous studies that suggested ICER nuclear 
expression; however, some of the transfected SK-MEL-24 cells showed the abnormal 
distribution for ICER expression. For instance, NWT and NKO samples showed higher 
numbers for ICER cytoplasmic localization than the nuclear distribution with values of 12 
and 24 respectively (Fig. 2). These results suggested that the transfected ICER mutants 
were affected by the activity and expression of other forms of ICER that were originally 
present in these melanoma cells with lower amounts.
In addition, another observation was made to study the morphology of the 
transfected SK-MEL-24 cells. To illustrate, we first compared the shapes of the mutants’
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nuclei to that of the control sample (Fig. 1). The immunostaining images showed that the 
nucleus of cells transfected with ICER mutants had different shapes as in K0-(52, 90 and 
97) samples which had an oval shaped nucleus observed under 200X total magnification 
(Fig. 1). Compacted nucleus was another type of modified nuclei observed for K0-(59, 70, 
71, 72, 76, 87, 100 and 106) samples. From these observations, we concluded that the 
activity of ICER mutants might be involved in disrupting the morphology of SK-MEL-24 
cells nuclei as well as dislocation of ICER.
Figure 1: Immunocytochemistry for ICER mutants in SK-MEL-24 cells. The images of the cells were viewed under 
200X total magnification. Scale bar = 10 gm.
16
Table 2: Cellular localization of ICER mutants. The data were estimated from 5 independent locations per sample.
Sample Nuc Avg.
Nuc+ Cyt 
Avg.
Control 0 0
CKO 11 8
NWT 8 12
CWT 44 29
KO-52 23 10
KO-59 21 8
K0-70 11 4
KO-71 29 14
KO-72 22 14
KO-76 22 11
KO-87 35 18
K0-90 27 20
KO-97 40 17
K0-100 22 14
K0-106 29 13
NKO 19 24
Figure 2: Plot indicating the numerical quantification of ICER cellular localization in SK-MEL-24 cells. Error bars 
show the standard error of 5 independent experiments.
Quantitative analysis of ICER in SK-MEL-24 cells
Because Immunocytochemistry can only give spatial data on the location of
expressed ICER mutants, Western Blot analysis was performed to further evaluate the
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expression levels of ICER mutants in SK-MEL-24 cells. Hence, we proposed a series of 
experiments to investigate quantitatively the amount of expressed ICER mutants at the 
cytosolic and nuclear levels. We first co-transfected SK-MEL-24 cells with ICER mutants. 
Then, the cells underwent NE-PER nuclear and cytosolic extractions. After that, a gel 
electrophoresis experiment was applied and the bands on the gel were transferred onto a 
nitrocellulose membrane through a Near-Infrared (NIR) Western Blot procedure. The 
immunoblotting images for all ICER mutants were obtained using Odyssey" CLx imaging 
infrared imaging system which showed how each mutant corresponded to the different 
levels of ICER expression (Fig. 3). The detected bands on the blotted membrane showed 
that ICER saturated at a molecular weight of T 8.5 KDa as compared to the provided protein 
ladder (Fig. 3, blue arrow). In addition, the data showed bands saturated at a lower 
molecular weight located below the bands for ICER protein and they represented that ICER 
most likely degraded (Fig. 3, green arrow). Furthermore, of ICER mutants had 
polyubiquitinated bands observed in the top region of the immunoblotted membrane (Fig. 
3, orange bracket). These observations in turn suggested that there was a process other than 
ubiquitination involved in the fate of ICER expression.
Moreover, the ratio of expressed ICER at the cytosol and nucleus was calculated from the 
intensity of each ICER mutants’ band obtained from the Odyssey® CLx infrared imaging 
program (Table 3). The results showed that ICER was expressed according to three 
categories; high intensity bands were detected in samples that were transfected with NWT, 
CWT, K0-(59 and 90), average intensity bands that were represented by ICER mutants 
CKO, NKO, K0-(52, 87 and 97), and low intensity bands that were collected from K0-(70, 
71, 72, 100 and 106) (Fig. 4). The Western Blot analysis provided more convenient
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information on the nature of ICER mutant expression on the cytosolic and nuclear levels 
which showed that it can be expressed at both sites. The data suggested that the decreased 
ICER expression in the nucleus was due to the abnormal activities of ubiquitination and 
sumoylation processes as post-translational modifications that took place after ICER 
cellular induction.
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___ JL
_  __ —..—  ICER
D *p*drd  1C ER
_y_ ___ 22___ £___
Pol> 'u b iq u m n a ted  1C F K
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Figure 3: Western Blot analysis for SK-MEL-24 cells transfected with ICER mutants. N represents nuclear fractions 
and C for cytosolic fractions. The assigned molecular weight for ICER is~ 18.5 KDa. The orange bracket shows the 
bands for polyubiquitinated ICER, the blue arrow shows bands for ICER and green arrow shows the bands for 
degraded ICER
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Table 3: Cellular localization of ICER mutants in SK-MEL-24 cells.
Sam ple
Cyt
Intensity
N uc
Intensity
N uc/C yt
Intensity
Control 0 0 0
CKO 1450000 2400000 166
N W T 484000 2920000 603
C W T 2310000 8150000 353
KO-52 144000 189000 131
K0-59 2700 7970 295
K 0-70 274000 139000 51
KO-71 1130000 36100 3
KO-72 1740000 122000 7
KO-76 1930000 27800 1
KO-87 173000 250000 145
K 0-90 40300 122000 303
KO-97 314000 559000 178
K 0-100 458000 322000 70
K 0-106 365000 203000 56
NKO 2180000 3640000 167
ICER Constructs
Figure 4: Plot indicating the quantification of the cellular localization of ICER mutants in SK-MEL-24 cells. The 
intensity ratio was calculated by dividing the intensity at the nucleus by the intensity of the cytoplasm times 100. 
Error bars show the standard error.
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ICER Mutants' Stability and Turnover
To investigate the nature and role of the ubiqitinated sites of all ICER mutants 
inside SK-MEL-24 cells, we performed a half-life experiment where the cells were first 
transfected with ICER mutants then treated with cycloheximide (CHX) assay to inhibit the 
de novo protein synthesis of ICER. Samples from each ICER mutant were collected at four 
different time intervals (0, 1,3 and 6 hours) and Western Blot analysis was applied to test 
the expression level of ICER mutant after CHX treatment (Fig. 5). The data showed that 
all ICER mutants expression levels have completely disappeared 6 hours after CHX 
application. The only samples that corresponded positively to the addition of CHX were 
CKO and NKO, which lack the presence of ICER, while the wildtype samples; NWT and 
CWT required shorter time to lose its levels for ICER expression indicating that cells 
carried out ubiquitination process after ICER protein translation.
Furthermore, to evaluate the amount of disappearance of ICER throughout the 
assigned time intervals, we measured the intensity of each band using the Odyssey51 CLx 
infrared imaging program (Table 4). The data showed that most of ICER mutants had a 
fast drop after two hours of treatment with CHX. The data collected at 3 hours showed a 
one-fold reduction in the activity of ICER expression and scored NWT and CWT with 
relatively higher intensities comparing to other samples with values of 52 and 60 
respectively, added to that, the data gave average intensities obtained from CKO and K0- 
71 with 22 values for both samples. On the other hand, the data at the 6th hour showed very 
low intensities for all samples, including NWT, CWT, KO-71 and K0-106 (Fig.6). These 
data in turn suggested that ICER underwent post-translation modifications which mainly 
highlighted the important role o f ubiquitination as well as shaded the light on the possibility
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that sumoylation pathway was another method triggering the SK-MEL-24 cells to get rid 
ofICER.
Figure 5: Western Blot analysis ofICER mutants’ half-life in SK-MEL-24 cells. The fractions were collected 
according to four different time intervals at (0, 1,3 and 6) hours.
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Table 4: Intensities of ICER mutants’ half-life. The intensities represent at four different time intervals (0, 1,3 and 6 
hours). Zero hours represent the time at which CHX was just added to each sample.
Hours
ICER
Constructs
0 1 3 6
NWT 100 60 52 25
CWT 100 80 60 44
NKO 100 33 9 4
CKO 100 48 22 12
KO-52 100 10 9 3
KO-59 100 12 4 2
K0-70 100 12 7 15
KO-71 100 14 22 25
KO-72 100 13 7 3
KO-76 100 12 8 12
KO-87 100 14 1 10
K0-90 100 19 13 6
KO-97 100 29 7 1
K0-100 100 20 10 7
K0-106 100 42 7 25
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Discussion
The purpose of this project was to elucidate how ICER expression and localization 
are altered by ubiquitination which tags the targeted proteins, allowing the cell to further 
signal for proteasomal degradation and sumoylation which only labels the targeted proteins 
and mislocate them on a subcellular level. By employing SK-MEL-24 mammalian 
melanoma cells, it was possible to perform site-directed mutation to further investigate the 
influence of post-translational modifications on ICER. Protein ubiquitination and 
sumoylation are key post-translational modifications that are involved in many aspects of 
cell behavior and malfunction and are related to a wide range of human diseases, including 
diabetes and cancer (33). We found that most ICER constructs were expressed at different 
levels in melanoma cells (Table 1). The estimated cell count and TE values showed that 
ICER mutants had diverse permeability toward SK-MEL-24 cells. This in turn indicated 
that modifying each ubiqitinated site of ICER through replacing the amino acid lysine (K) 
to arginine (R) caused a transformation to the chemical and conformational properties 
which affected the affinity of ICER mutants and their overall expression profile.
Earlier melanoma studies have stated that ICER expression occurs only on the 
nucleus level of the cell (32); nevertheless, we have provided a fundamental evidence 
suggesting that ICER cellular localization was detected in the nucleus and cytoplasm of 
SK-MEL-24 cells (Fig. 1). Here, we hypothesized that the endogenous ICER acted as a 
strong competitive substrate on the promoter of CREB leading the cells to exclude the 
transfected ICER mutants from the nucleus to the cytoplasm. This occurred because ICER 
protein is relatively small and can diffuse through the pores of the nucleus. In addition, it 
has previously been shown that PTMs like ubiquitin and ubiquitin-like-dependent
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pathways have a significant function in regulating cellular responses to different changes 
such as degradation of the endogenous proteins through proteasome (15, 18). In human 
melanoma cells, ICER proteasomal degradation is promoted by MAPK or cdkl 
phosphorylation where it is tagged with ubiquitin leading to degradation through 
polyubiquitination or mistargeted to the cytosol through monoubiquitination (27). Using 
Western Blot analysis, we found that ICER was only polyubiquitinated and represented by 
a smear of bands with different molecular weights resided above the band for ICER (Fig.3). 
This in turn, suggested that ICER was targeted for proteasomal degradation. Elowever, our 
data did not show any monoubiquitinated form of ICER obtained from the blotted 
membrane, we observed a degraded form of ICER represented by a group of bands traced 
below ICER band. We hypothesized that ICER might have reacted with the antibody and 
produced protein with lower molecular weights (Fig.3). Moreover, previous studies have 
indicated that the biological implications of sumoylation pathway can modify the fate of 
protein expression within the subcellular component o f tumor cells (21). We found that 
most of ICER mutants were expressed in the cytosol of SK-MEL-24 cells (Fig. 3). From 
these data, we hypothesized that ICER was not targeted for proteasomal degradation, 
rather, it was only labeled with ubiquitin-like molecule through occupying the same lysine 
(K) residue required for the ubiquitination process, masking its function and consequently 
mislocating ICER expression into the cytosol. Since sumoylation involves in non- 
proteolytic targeting, its biochemical function affects the non-covalent interactions 
between the modified protein and the sumo interacting motifs (SIM) facilitating various 
interactions and promoting configurational changes (21). Based on these previous
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discoveries, we hypothesized that the different cellular distribution of ICER mutants’ 
expression was due to these interactions (Table 3 and Fig. 4).
Furthermore, determining the stability and turnover of ICER protein are considered 
the most crucial step towards exploring whether its biological activity and cellular 
expression level are undergoing proteolytic control as in the case of ubiquitination and 
sumoylation. Through the application of specific inhibitors that are designed to target 
different proteolytic proteins it will be a very useful tool for identifying specific protein 
degradation pathways. Therefore, we sought to employ the half-life approach using the 
blocker cycloheximide (CHX) to further understand the turnover properties of ICER 
mutants on the cellular level. We found that all ICER mutants had a very short lifespan 
averaged to be between 1-3 hours (Fig. 5 and table 4). Here, we hypothesized that the N- 
terminus was very important for the stability of ICER and by adding the HA-tag, it might 
lead to camouflaging this stability. This in turn indicated that lysine (K) residue is very 
important for the activity of ICER. In addition, the results suggested that the cells were 
triggering other pathways to get rid of ICER.
It has been clear that any alteration in gene expression coupled to the activation of 
certain cellular signaling pathway leading to abnormal cellular proliferation and 
dysregulating the fate of mammalian cells have long been identified as the most 
distinguished features o f cancer progression. These activities are promoted by PTMs 
because of their chemical modifications in regulating or changing proteins’ function and 
structures, which in turn are responsible for dictating the different activation states for most 
of the biological and physiological events. This project discusses two of the most of well- 
established examples PTMs; ubiquitination and sumoylation where they control the fate of
26
ICER protein, resulting in the irregularities of cell physiology, anatomy, cellular
localization integrity and gene expression levels.
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